Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis - Top-Institutions - MDSpire

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

Baptist Health Brain & Spine Care is enrolling patients with confirmed multiple sclerosis who are starting BRUMVI to track outcomes, safety, and patient experience over time in a real-world setting.

  • By

  • March 4, 2026

  • 2 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Multiple Sclerosis
    • Neuroimmunology

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Neurology
    • Multiple Sclerosis
    • Neuroimmunology

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Multiple Sclerosis
    • Neuroimmunology

  • #4

    Baptist Health South Florida
    Baptist Health South Florida

    Miami, FL

    Key Differentiators

    • Neurology
    • Multiple Sclerosis

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Multiple Sclerosis
    • Neuroimmunology

Original Source(s)

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

  • by

  • March 4, 2026

Related Content

Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

CAR-T cell therapy embarks on autoimmune disease